Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + vincristine + cyclophosphamide + l-asparaginase + dexamethasone
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
This is a **combination chemotherapy regimen** consisting of five agents: - **Pegylated liposomal doxorubicin** is an anthracycline chemotherapy encapsulated in polyethylene glycol-coated liposomes for enhanced tumor uptake and reduced cardiotoxicity. It acts by inhibiting topoisomerase II, preventing DNA replication and promoting apoptosis in rapidly dividing cells[1][2][8][9]. - **Vincristine** is a vinca alkaloid that binds to tubulin and inhibits microtubule formation, halting mitosis in dividing cells. - **Cyclophosphamide** is an alkylating agent that cross-links DNA, resulting in cell death. - **L-asparaginase** is an enzyme that depletes extracellular asparagine, inhibiting protein synthesis in leukemic cells that cannot synthesize asparagine. - **Dexamethasone** is a synthetic glucocorticoid used to reduce inflammation, suppress immune response, and as an antiemetic adjunct to chemotherapy[3][6]. This regimen provides a multi-modal approach to antineoplastic therapy, combining DNA damage, mitotic arrest, metabolic blockade, and immune modulation. It may be used for treatment of various hematological malignancies and solid tumors, based on established protocols and the inclusion of these agents in regimens for lymphomas and leukemias[4][5].
- Other names
- pegylated liposomal doxorubicin + vincristine + cyclophosphamide + l-asparaginase + dexamethasone
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + vincristine + cyclophosphamide + l-asparaginase + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + vincristine + cyclophosphamide + l-asparaginase + dexamethasone.